GeneSAFE™ is the first non-invasive prenatal test that screens for both de novo and inherited single-gene disorders.
Current non-invasive prenatal tests screen for aneuploidies and microdeletions. PrenatalSAFE® Karyo also screens for rare aneuploidies and segmental chromosome imbalances (gains and losses) in every chromosome in the fetal genome, providing karyotype-level insight.
GeneSAFE™ goes further...
Through cfDNA analysis from maternal plasma, it screens for several clinically significant and life-altering genetic disorders that are not screened for with current NIPT technology.
GeneSAFE™ involves 3 different levels of screening:
screens for 5 common inherited recessive genetic disorders
screens for 44 severe genetic disorders due to de novo mutations (a gene mutation that is not inherited)
screens for both inherited and de novo single-gene disorders, providing a more complete picture of the pregnancy risk.
The most comprehensive information available from a non-invasive prenatal test to date
GeneSAFE™ works as a complementary screen to traditional or genome-wide NIPT (such as PrenatalSAFE® Karyo), allowing a complete picture of the risk of a pregnancy being affected by a genetic disorder.